Episodit
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kerstin Dolph, Senior Vice President of Manufacturing at Charles River Laboratories.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kerstin, covering:
The value of having managers and mentors guide you and champion your successNavigating transitions from finance to operations and research to biologics manufacturing while becoming a senior leader at CRLTackling the task of integrating testing and manufacturing at CRL globally to cut timelines for clientsThe importance of staying close and connected to the patient so you never lose sight of the impact of the work done in this spaceStabilizing signs in the biotech market and pivoting to the market's needs in creative waysKerstin joined Charles River 2001 in a Finance role for the Company’s Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and was promoted to Senior Finance Director of Global RMS in 2015.
In 2017, Ms Dolph was promoted to Corporate Vice President of North American RMS, responsible for leading the Company’s North American RMS business. This included managing several consolidation and efficiency initiatives and global RMS technology enhancements.
In 2019, Ms Dolph assumed the role of Corporate Vice President of Global Biologics. Subsequently, she assumed responsibility for the Company’s CDMO business and was promoted to senior vice president of biologics solutions in October 2021. Ms. Dolph is currently the Senior Vice President of Manufacturing. She is responsible for driving each business's strategic direction and future growth within the Company’s Manufacturing Solutions segment, including Biologics Testing Solutions, CDMO, and Microbial Solutions.
Ms. Dolph holds a bachelor’s degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognised by the Bavarian Government for outstanding performance.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jack Stine, Chief Executive Officer at Savendor.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jack, covering:
What he learned about supplier relationship management from exposure to 70 supply chain sourcing teams in 3MThe shift to sourcing APIs and excipients for generics and med devices under FDA regulationsHow he always wanted to start a business, take the plunge, and fall in love with being a founderThe actual trend of secondary sourcing... as opposed to immediate switchingAnd what is Minnesota nice?!Since founding Savendor in 2023, Jack Stine has pioneered a new model for pharma sourcing teams to move faster, cut out intermediaries, added clients from 4 continents, and built an industry-leading portfolio of 331 pharmaceutical ingredient manufacturers. Savendor has been accepted into AstraZeneca’s Diverse and Small Business Mentorship Program and BetaMN’s startup accelerator. Jack has presented Savendor at both CPHI Philadelphia and CPHI Milan.
Jack has worked in sourcing for over a decade. His career has brought him to APIs, excipients, industrial products, services, food, and medical device components. He has shared his knowledge by leading the Negotiations Training Team at Boston Scientific and speaking to undergraduates at the University of Minnesota’s Carlson School of Management. Jack has a Supply Chain Management Degree from the University of Minnesota and an MBA from IE Business School. Beyond sourcing and supply chain, Jack volunteers his time at the Ukrainian American Community Center as he is passionate about supporting people affected by the war in Ukraine.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
Puuttuva jakso?
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering:
How Tessa's bullish attitude led to her becoming a co-founder at PharmaReviewBeing the 'less educated person in the office', and using that to drive the growth of the businessOpting not to leave after the sale of the business, and becoming the CEOBeing the star player within a PE portfolio, leading to a quick exit to IQVIALife lessons on having your cake...and eating it!Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality.
Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world’s leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr Camilla Easter, CEO at Oxford Medical Products.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering:
Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotechFalling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytellingOMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetiteDeveloping a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe mannerHow OMPs unique, patented manufacturing process led it to in-house production and not outsourcingLifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trialsCamilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices.
Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020.
OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Akshay Peer, co-founder and Senior Vice President of Products at TrakCel.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Akshay, covering:
How the development of a patent led him into the CGT space—years before it was a marketThe founding story of TrakCel and getting GSK as an anchor client to support early iterations of its custom solutionFresh-in, frozen-out... just one of the variations of biospecimens to product in the crazy complex CGT supply chainStandardizing, streamlining, and harmonizing will become the de facto software choice for the avalanche of CGTs predicted to be approved by 2030The decision to seek strategic investors (instead of financial investors) and the advantages it has brought to TrakCelAkshay is a co-founder and currently serves as the Senior Vice President of Product at TrakCel. Before this, he worked as the Business Development Lead for TrakCel for 8 years, from 2012 to 2018. He then took a break and worked as the CGT lead for Bluecrux.
After a two-year hiatus, Akshay rejoined TrakCel’s team in September 2023 as the new head of product. He is an expert in software solutions to address the challenges of scaling cell and gene therapy products. Akshay has worked with companies developing autologous, allogeneic, CRISPR Cas-9, and other technology-based products.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with John Fowler, President & CEO at Pii (Pharmaceutics International, Inc.)
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with John, covering:
How a competitive family environment and navigating flight school in the Navy equipped him for a successful careerWhy a CDMO business is like managing chaos... under strict regulationsThe silver lining of the pandemic - quality time with his familyWhy he decided to leave Johnson Matthey after 30 years and take a 'title' step backBringing PII back to its former glory and rebuilding a management teamJohn Fowler brings more than 30 years of pharmaceutical and chemical industry experience to Pii. He most recently served as President and Chief Operating Officer of Piramal Pharma Solutions, a CDMO serving generic companies worldwide. Before joining Piramal, he was the Divisional CEO of the Global Fine Chemical business at Johnson Matthey.
Mr. Fowler also held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts, and Technologies. He has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
Dirk Lange, CEO at Pyramid LabsBrett Alderson, President & Site Leader at NovaCinaJohn Cameron, Director, Global Injectables Platform at Corden PharmaJanet Hoogstraate, CEO at NorthX BiologicsYour host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:
Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilitiesIndustry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOsMeeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatmentsStrategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sectorWith GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Stevenson, Independent Director and Pharma industry veteran.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:
Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IPBehind the scenes of Pfizer's mammoth acquisitions of Wyeth and HospiraThe failure to spend too much time setting up a reliable, high-quality outsourcing network in ChinaThe different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across severalSwitching from buy-side external outsourcing to running Pfizer's CDMO division Pfizer CentreOneDon't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industryPeter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer’s Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma.
Later, Mr. Stevenson served as General Manager of Pfizer’s contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.
Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jen Nwankwo, Founder and CEO at 1910 Genetics.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jen, covering:
Being the first PHD at Bain's Global HQ, and what she learned from the experienceHow she stumbled across AI and open innovation as it applied to R&D productivity, and accelerating clinical trialsThe founding story of 1910, and fundraising as an African American female entrepreneur and going on to be backed by Sam Altman, CEO of OpenAI, Y Combinator and Microsoft...Signing a five-year agreement with Microsoft to create an AI-driven drug discovery and development platform that helps R&D teams generate drugs faster and cheaperWhy artisanal and serendipitous drug development does not cut it. And the spectrum of AI experts Vs AI novices in pharma... and why a 'FOMO attitude' will lead to 'pilot fatigue', and slow adoptionBefore founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Karen Lackey, CEO at X-Chem.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Karen, covering:
Why diversity of thought is essential in solving problems that have never been solved beforeWhy did she leave the big pharma world after 30 years to join the world of academia? And how joining a global CRO enabled Karen to democratize its tech and platformsWhy she's taking her decades of drug discovery experience to help redefine it at X-ChemUsing AI/ML more holistically to make its innovative platform more accessible and capital-efficient to biotechs dealing with challenging small molecule projectsHer view on biotech failures and fragmented space and the need to rethink ways to launch biotechsKaren Lackey is the Chief Executive Officer of X-Chem, a company dedicated to delivering on the promise of a leading small molecule drug discovery partner with unmatched excellence in DNA encoded library technology, digitized drug discovery, and discovery chemistry.
Karen's over 30-year career encompasses international leadership roles within Pharma (GSK, Roche), Academia (MUSC, UA), Biotech (e.g. PyramidBio, BlinkBio, Centauri, Aurobac), Foundations/Charities (e.g. CRUK, TI Horizons) and most recently with the CRO Evotec. She is a passionate drug hunter, playing a pivotal role in discovering Tykerb, and contributing to the advancement of numerous clinical candidates and launched drugs.
Throughout her distinguished career, Karen has been at the forefront of integrated drug discovery, spanning diverse areas such as machine learning/AI/computational chemistry, medicinal chemistry, chemical biology, biochemistry, discovery biology, pharmacology, DMPK, and the application and integration of new technologies.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Emma Banks, CEO at ramarketing.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Emma Banks, CEO at ramarketing, covering:
How a conversation with her late father led Emma to look out for herself and jump into the unknownThe contrast of two different CEO roles - stepping from a hand-to-mouth cash-strapped tech business into a rapid-growth businessWhy Emma decided to do the UNTHINKABLE...and work with Raman to run ramarketingThe one piece of advice that has helped Emma navigate being a CEO under PE ownershipAnd why, despite some challenges on the horizon...the only way is up for the pharma services spaceHaving spent over 20 years of experience in the industry with a focus on clinical research and a former board member of the Society of Clinical Data Management (SCDM), Emma is a seasoned expert in the global pharmaceutical and life sciences contract services sector.
After earning a PhD in Immunology and two years of postdoctoral research, Emma led the data management team at a small biometrics CRO before going on to run an international life sciences software business.
Today, Emma heads up ramarketing, overseeing growth plans across North America and Europe, ensuring exceptional service to clients looking to grow in life sciences.----more----
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.----more----
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rani Powers, Founder & CEO at Pluto Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering:
Her passion for coding and what drew her into the world of biologyHow the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-upThe value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologistsSpinning out her company from the Wyss Institute at Harvard University... in a non-conventional wayHow the adoption and implementation of AI is just getting started... and how it will evolveDr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster.
She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:
The epidemiological challenge of rare diseases and representing the topic at the White HouseWhy is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZenecaSome top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your championsTamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity.
Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.
Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:
How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market capWhy the biotech space had such a market downturn, and how the uptake in the industry will be data-drivenDemystifying the role of a biotech CEO and understanding what it takes to drive successful drug developmentWhy relying on outsourcing is critical for biotechs todayThe emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled?Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech.
Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group.
-----
Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing.
Find out more and pre-register here
-----
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kent Payne, CEO at Aliri Bioanalysis.
Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering:
Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to marketThe formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilitiesHe shares his core principles playbook for getting a company back on track and on a path for growthThe value of getting scientists in front of the client to build relationships and demonstrate technical know-howThe strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the marketHow Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotechDr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company)
Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year. Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations. He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference. Simply email [email protected] to learn more.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA).
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:
The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belongHow the industry has evolved over the last few years after Covid, including harder times and areas of green shootsWhy Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrendA deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 yearsThe need to know market headwinds and tailwinds that you simply cannot ignoreGil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference.
Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering:
Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovationThe transformation of quality components and complex assemblies to game changing systems and solutionsHow SaniSure differentiates from smaller and larger bioprocessing organizationsWhy exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy)Making the bioprocessing supply chain more robustSaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp
-
In this mid year episode special, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering:
The anticipated recovery of the biotech sector and where it stands now Geopolitical influences on the life sciences industry, with a focus on the CDMO sector Exciting upcoming episodes and insights to watch for in the next few weeks Where to meet Raman at upcoming trade shows across North America & Europe Sectors powering through industry challenges, including early-stage development and AI-driven drug discoverySubscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Yussuf Goolam, Co-Founder, President and CEO at RxSource.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Yussuf, covering:
His family's journey from Mozambique to North America and the value of having an entrepreneurial ethosLifelong business lessons from a window cleaning job... and the impact of going on a learning rampageThe real-life grind of getting a business off the ground and always being willing to chase an opportunityThe pivot that led to becoming a global partner for clinical trial supplies and not just a transactional sourcing supplierThe importance of purpose, mission, values, culture and clarity in building a fiercely loyal and fulfilled workforceAfter co-founding RxSource in 2005, Yussuf’s initial focus was developing and expanding the company’s brand and client base globally. In early 2020, he assumed a new role as President and CEO and guided the organisation through a significant transformation. Since shifting the focus to clinical trial supply chain services, the company has grown to over 60 team members worldwide, supporting CROs, biotechs, and sponsors.
With over 20 years of experience in the niche pharmaceutical sector, he is dedicated to building a purpose-driven company by supporting a team of high-performing individuals to achieve their personal and professional goals together.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Cook, CEO at Sterling Pharma Solutions.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:
Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of SterlingThe power of a rebrand and sense of togetherness to gain commercial tractionKevin’s five-point M&A playbook that’s helped drive exponential, transatlantic growthWhy culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sitesThe robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the futureKevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant.
In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions.
In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
- Näytä enemmän
